Evaluation of the pan‐class I phosphoinositide 3‐kinase (PI3K) inhibitor copanlisib in the Pediatric Preclinical Testing Consortium in vivo models of osteosarcoma-Reference-Cited by-同舟云学术

Evaluation of the pan‐class I phosphoinositide 3‐kinase (PI3K) inhibitor copanlisib in the Pediatric Preclinical Testing Consortium in vivo models of osteosarcoma

Published:2022-10-17 Issue:1 Volume:70 Page:
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatric Blood & Cancer

Author:

Harrison Douglas¹^ORCID,Gill Jonathan¹^ORCID,Roth Michael¹^ORCID,Hingorani Pooja¹,Zhang Wendong¹,Teicher Beverly²,Earley Eric³^ORCID,Erickson Stephen³,Gatto Gregory³,Kurmasheva Raushan⁴^ORCID,Houghton Peter⁴,Smith Malcolm²,Anders Kolb E.⁵,Gorlick Richard¹

Affiliation:

1. Division of Pediatrics University of Texas MD Anderson Cancer Center Houston Texas USA

2. Cancer Therapeutics Evaluation Program National Cancer Institute Bethesda Maryland USA

3. Global Health Technologies RTI International Research Triangle Park North Carolina USA

4. Greehey Children's Cancer Research Institute University of Texas Health Science Center at San Antonio San Antonio Texas USA

5. Division of Pediatric Hematology/Oncology Nemours/Alfred I. duPont Hospital for Children Wilmington Delaware USA

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pbc.30017

Reference20 articles.

1. Osteosarcoma treatment – Where do we stand? A state of the art review

2. Current and future therapeutic approaches for osteosarcoma

3. Phase II/III Trial of Etoposide and High-Dose Ifosfamide in Newly Diagnosed Metastatic Osteosarcoma: A Pediatric Oncology Group Trial

4. Osteosarcoma Relapse After Combined Modality Therapy: An Analysis of Unselected Patients in the Cooperative Osteosarcoma Study Group (COSS)

5. Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move Forward

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeted Inhibition of the PI3K/Akt/mTOR Signaling Axis: Potential for Sarcoma Therapy;Mini-Reviews in Medicinal Chemistry;2024-09

2. Collaborative Innovations in Childhood Cancer Therapies;Handbook of Experimental Pharmacology;2024

3. Discovery of potent and selective PI3Kδ inhibitors bearing amino acid fragments;Bioorganic Chemistry;2023-09